PathoCapital
VC Fund
Northbrook, United States
PathoCapital is a venture fund that finances companies in the healthcare industry.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries PathoCapital invests in
Stages PathoCapital invests in
Countries PathoCapital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Wilbur Gantz
|
|||
Investment Focus
Industry
- Medical 2 (40%)
- Biopharma 2 (40%)
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Wearables 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Series C 1 (20%)
- Funding Round 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Wilbur Gantz
President and CEO
|
President and CEO | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aptinyx
|
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. | $70M / Series B / Dec 18, 2017 | |
ReliefBand Technologies
|
ReliefBand Technologies designs and develops digital wearable devices that provide therapies for nausea and morning sickness associated with motion, morning, chemotherapy, and as an adjunct to post-op nausea. Its therapeutic device offers a clinically proven, FDA cleared wearable technology for the treatment of nausea and vomiting associated withmotion sickness, morning sickness, and VR Gaming chemotherapy and as an adjunct to post-op nausea, and offers pre-programmed pulses with specific waveform, frequency, and intensity of stimulation for the median nerve on the underside of the wrist, that enable users to treat nausea and vomiting in a drug-free manner by just wearing a wristband.ReliefBand Technologies was established in 2015 and is headquartered in Horsham, Pennsylvania. | $5M / Dec 15, 2015 | |
Naurex
|
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $80M / Series C / Dec 03, 2014 | |
|
Naurex
|
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $38M / Series B / Dec 17, 2012 | |
|
Naurex
|
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $18M / Series A / May 11, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does PathoCapital invest in?
PathoCapital invests primarily in Medical, Biopharma and Health Care startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact PathoCapital?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at PathoCapital?
The team at PathoCapital includes Wilbur Gantz (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
